<DOC>
	<DOCNO>NCT02684123</DOCNO>
	<brief_summary>Alopecia areata medical condition , hair fall patch . The hair fall scalp elsewhere face body . Alopecia areata autoimmune skin disease , mean immune system recognize hair follicle foreign attack , cause round patch hair loss . It progress total scalp hair loss ( alopecia totalis ) complete body hair loss ( alopecia universalis ) . The scalp commonly affect area , beard hair-bearing site affect alone together scalp . Alopecia areata occur male female age , highly unpredictable condition tend recur . Alopecia areata cause significant distress patient family . In study , aim ass effect new treatment call apremilast patient alopecia areata . A total 30 patient include study , run total 52 week .</brief_summary>
	<brief_title>Pilot Study Safety Efficacy Apremilast Subjects With Moderate Severe Alopecia Areata</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled pilot study consist two phase . A total 30 subject moderate severe alopecia areata ( include universalis totalis ) involve 50-100 % scalp enrol . A possible maximum 15 patient ( approximately 7 patient ) current episode AA totalis / universalis may include study . In Phase 1 , subject randomize ( 2:1 ) either receive apremilast placebo 24 week . In Phase 2 , eligible subject receive apremilast Week 24 Week 48 . The following subject eligible enter Phase 2 : 1 . Subjects receive placebo Phase 1 study 2 . Subjects receive apremilast Phase 1 study , achieve minimum 50 % regrowth ( SALT50 ) Week 24 , compare Baseline .</detailed_description>
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<mesh_term>Apremilast</mesh_term>
	<mesh_term>Thalidomide</mesh_term>
	<criteria>Males female , 18 year old time signing informed consent document . Understand voluntarily sign informed consent document prior studyrelated assessments/procedures conduct . Able adhere study visit schedule protocol requirement . Subject diagnosis patchy scalp alopecia areata present least 6 month , maximum 10 year . Patients ≥50 % &lt; 95 % total scalp hair loss Baseline measure use SALT score qualify moderate severe AA ; 95 % 100 % scalp hair loss qualify AA totalis/universalis . Must meet follow laboratory criterion White blood cell count ≥ 3000/mm3 ( ≥ 3.0 x 109/L ) &lt; 14,000/mm3 ( &lt; 14 x 109/L ) . Platelet count ≥ 100,000/μL ( ≥ 100 x 109/L ) . Serum creatinine ≤ 1.5 mg/dL ( ≤ 132.6 μmol/L ) . AST ( SGOT ) ALT ( SGPT ) ≤ 2 x upper limit normal ( ULN ) . If initial test show ALT AST &gt; 2 time ULN , one repeat test allow Screening Phase . Total bilirubin ≤ 2 mg/dL ( 34 μmol/L ) . If initial test show total bilirubin &gt; 2 mg/dL ( 34 μmol/L ) , one repeat test allow Screening Phase . Hemoglobin ≥ 10 g/dL ( ≥ 6.2 mmol/L ) . Females childbearing potential ( FCBP ) must negative pregnancy test Screening Baseline . While investigational product least 28 day take last dose investigational product ( IP ) , FCBP engage activity conception possible must use one approve contraceptive option describe : Option 1 : Any one follow highly effective method : hormonal contraception ( oral , injection , implant , transdermal patch , vaginal ring ) ; intrauterine device ( IUD ) ; tubal ligation ; partner 's vasectomy ; OR Option 2 : Male female condom ( latex condom nonlatex condom NOT make natural [ animal ] membrane [ example , polyurethane ] ) ; plus spermicide PLUS one additional barrier method : ( ) diaphragm spermicide ; ( b ) cervical cap spermicide ; ( c ) contraceptive sponge spermicide . Male subject ( include vasectomy ) engage activity conception possible must use barrier contraception ( male latex condom nonlatex condom NOT make natural [ animal ] membrane [ example , polyurethane ] ) IP least 28 day last dose IP . No evidence hair regrowth present Baseline . EXCLUSION CRITERIA : The presence follow exclude subject enrollment : Clinically significant ( determined investigator ) cardiac , endocrine , pulmonary , neurologic , psychiatric , hepatic , renal , hematologic , immunologic disease , major uncontrolled disease affect health subject study interfere interpretation study result . Hepatitis B surface antigen positive Screening ( Visit 1 ) . Hepatitis C antibody positive Screening ( Visit 1 ) . History positive human immunodeficiency virus ( HIV ) , congenital acquire immunodeficiency ( eg , Common Variable Immunodeficiency [ CVID ] ) . Subjects deem risk study investigator , may also undergo test human immunodeficiency virus ( HIV ) . Subjects deem risk include history injection drug use , homosexual subject , subject know sexual contact HIV positive partner . Active TB history inadequately treat TB . Active substance abuse history substance abuse within six month prior Screening . Pregnant breast feeding . History allergy component IP . Major surgery within eight week prior Screening ( Visit 1 ) and/or plan surgery length study . Malignancy history malignancy , except : treat ( ie , cure ) basal cell squamous cell situ skin carcinoma ; treat ( ie , cure ) cervical intraepithelial neoplasia ( CIN ) carcinoma situ cervix evidence recurrence within 5 year prior Screening ( Visit 1 ) . Unstable asthma ( eg , acute episode exacerbation [ nocturnal episode , sudden episode trigger unidentifiable factor ] despite stable regimen antiasthmatic medication ) ; prior episode ( ) lifethreatening asthma ; asthma require inhaled budesonide equivalent &gt; 1200 μg/day fluticasone propionate &gt; 880 μg/day along another antiasthmatic drug longacting betaagonist . A history and/or concurrent condition serious hypersensitivity ( eg , anaphylaxis ) drug , food , allergen without access emergency rescue medication epinephrine . Persistent recur bacterial infection require systemic antibiotic , clinically significant viral fungal infection , within two week Screening ( Visit 1 ) . Any treatment infection must complete least two week prior Screening Visit new/recurrent infection occur prior Baseline Visit . Active skin infection require systemic antimicrobial Baseline/Randomization ( Visit 2 ) . Skin lesion ( ) due condition AA would interfere study specified assessment . Prior treatment apremilast , participation clinical study involve apremilast . Use phototherapy ( ie , UVB , UVA ) systemic immunosuppressive drug ( include , limited , cyclosporine , corticosteroid , mycophenolate mofetil , azathioprine , Methotrexate , tacrolimus ) , oral preparation herbal immunomodulatory medication within four week prior Baseline/Randomization ( Visit 2 ) . Use interferonγ within 12 week prior Baseline/Randomization ( Visit 2 ) . Use abatacept , adalimumab , certolizumab pegol , etanercept , golimumab , infliximab , tocilizumab within 12 week prior Baseline/Randomization ( Visit 2 ) . Use oral janus kinase ( JAK ) inhibitor ( e.g . tofacitinib , ruxolitinib ) within 12 week prior Baseline/Randomization ( Visit 2 ) . Use omalizumab , rituximab , ustekinumab , alefacept , briakinumab , therapeutic antibody product within 24 week prior Baseline/Randomization ( Visit 2 ) . Use investigational drug within four week five PK PD half life ( whichever longer ) prior Baseline/Randomization ( Visit 2 ) . Use topical corticosteroid preparation , topical calcineurin inhibitor , topical preparation immunomodulatory property within 2 week prior Baseline/Randomization ( Visit 2 ) . Prior history suicide attempt time subject 's lifetime prior Baseline ( Visit 2 ) major psychiatric illness require hospitalization within 3 year prior Baseline ( Visit 2 ) . History male female pattern hair loss Ludwig stage III Hamilton &gt; stage V. Patients diagnosis alopecia areata question , subject scar alopecia .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Alopecia areata</keyword>
</DOC>